Title |
The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer—a pooled analysis of the randomised clinical trials PlanB and SUCCESS C |
|---|---|
Involved |
Amelie de Gregorio (Verfasser)
Wolfgang Janni (Verfasser) Thomas W. P. Friedl (Verfasser) Ulrike Nitz (Verfasser)
Brigitte Rack (Verfasser)
Andreas Schneeweiss (Verfasser) Ronald Kates (Verfasser) Tanja Fehm (Verfasser) Hans Kreipe (Verfasser) Matthias Christgen (Verfasser) Sherko Kümmel (Verfasser) Elisabeth Trapp (Verfasser) Rachel Wuerstlein (Verfasser) Andreas Hartkopf (Verfasser) Michael Clemens (Verfasser) Toralf Reimer (Verfasser) Lothar Häberle (Verfasser) Peter Andreas Fasching (Verfasser) Oleg Gluz (Verfasser) Nadia Harbeck (Verfasser) SpringerLink (Online service) (Sonstige) |
Published in |
British journal of cancer : BJC 126, 12, 22.2.2022, date:6.2022, Seite 1715-1724 |
Published |
2022 |
Language |
|
Country |
|
Topic |
|
Subject |
Biomedicine, general.
Cancer Research. Epidemiology. Molecular Medicine.
Oncology.
Drug Resistance. |
DDC notation |
|
Persistent identifier |
urn:nbn:de:101:1-2022080419521647980479 (URN) |
Record ID |
1264471440 |
Please note
The beta version does not yet contain all functions and information of the DNB portal catalogue. If you are missing information or want to order a medium, please visit the page in the DNB portal catalogue via the following link: